A single dose of ibogaine in mice produces a complex, long-lasting pattern of modulation of NMDA receptors, a brain receptor type involved in addiction. Ibogaine inhibited convulsions induced by NMDA at 24 and 72 hours after treatment, and binding to NMDA receptors was also significantly decreased at those times. No effects were seen at 30 minutes or 48 hours. This sustained, non-continuous modulation may underlie ibogaine's ability to reduce withdrawal and craving for extended periods after a single dose.
Ibogaine, a compound proposed as a potential treatment for addiction, affects glutamate handling in brain cells. In mouse cortical synaptosomes, high concentrations of ibogaine (500–1000 µM) inhibited glutamate uptake and stimulated its release, while having no effect on rat synaptosomes or cerebellar synaptosomes. Additionally, ibogaine (1000 µM) nearly abolished glutamate uptake by cortical astrocyte cultures from both rats and mice. These results provide direct evidence that ibogaine alters glutamate handling in specific brain regions and support cells, linking its mechanism to neurotoxicity rather than therapeutic effects.
A microwave-assisted chemical reaction was used to create a key intermediate for synthesizing ibogaine analogues. One analogue, a hydroxymethyl indolyl derivative, showed promising binding to dopamine, serotonin, and opioid receptors in lab tests and reduced withdrawal symptoms in mice. Simplifying the ibogaine molecule appears to be a useful strategy for designing new compounds to treat addiction withdrawal.